CLAIMS

1. A compound of formula (I) and pharmaceutically acceptable salts or solvates thereof:

5

2. A compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as claimed in claim 1 for use in therapy.

10

3. A compound, pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to claim 1 for use as a medicament for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis

15

- 4. A compound, pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to claim 1 for use as a medicament for the treatment of cancer.
- 5. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate 20 thereof, as claimed in claim 1 in the manufacture of a medicament for use in therapy.
- 6. A method of treating a chemokine mediated disease wherein the chemokine binds to one or more chemokine receptors, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.

7. A method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.

5

8. A method of treating a disease in which angiogenesis is associated with raised CXCR2 chemokine levels, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.

10

9. A process for the preparation of a compound of formula (I) which comprises reaction of a compound of formula (II):

15

(II)

where R is C_{1-6} alkyl with an acid, and optionally thereafter forming a pharmaceutically acceptable salt.

- 20

10. A combination therapy which comprises administering a compound of formula (1) or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, or a pharmcaceutical composition or formulation comprising a compound of formula (1), concurrently or sequentially with other therapy and/or another pharmaceutical agent.

10

- 11. A combination therapy as claimed in claim 10 for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis.
- 5 12. A combination therapy as claimed in claim 10 for the treatment of cancer.
 - 13. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
- 14. A pharmaceutical composition as claimed in claim 13 for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis.
- 15 15. A pharmaceutical composition as claimed in claim 13 for the treatment of cancer.
- 16. A process for the preparation of a pharmaceutical composition as claimed in claim 13 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 with a pharmaceutically acceptable adjuvant, diluent 20 or carrier.